-The role of the kidney in calcium homeostasis has been reshaped from a classic view in which the kidney was regulated by systemic calcitropic hormones such as vitamin D3 or parathyroid hormone to an organ actively taking part in the regulation of calcium handling. With the identification of the intrinsic renal calcium-sensing receptor feedback system, the regulation of paracellular calcium transport involving claudins, and new paracrine regulators such as klotho, the kidney has emerged as a crucial modulator not only of calciuria but also of calcium homeostasis. This review summarizes recent molecular and endocrine contributors to renal calcium handling and highlights the tight link between calcium and sodium reabsorption in the kidney.
calcium; hypercalciuria; kidney stones; osteoporosis; sodium; nephrocalcinosis KIDNEYS ARE MAJOR REGULATORS of calcium homeostasis. This is illustrated by the profound and complex dysregulation of mineral metabolism appearing during chronic kidney disease (CKD) recognized as mineral and bone disorders in chronic kidney disease (MBD-CKD).
Fluxes of calcium between the small intestine (the place for calcium absorption), the bone (the main storage place for calcium), and the kidney (the main place of elimination of the absorbed calcium) are highly controlled by numerous transport mechanisms, hormones, and interconnected feedback loops. This is an absolute requirement to prevent unwanted biomineralization in tissues. Indeed, calcium is a highly reactive ion which has high propensity to form microcrystals in fluids and tissues. In mammals, the complex process of biomineralization takes place in a controlled manner in teeth and bones, in which the matrix is calcified with hydroxyapatite, a calcium-phosphate salt. As the calcification process necessitates interactions between matrix proteins and high local calcium and phosphate concentrations at a specific pH, keeping calcium in solution also demands significant effort. With plasma concentrations of ϳ2.4 mmol/l for calcium and 1 mmol/l for phosphate, crystallization would spontaneously occur, if inhibitors of calcification, such as magnesium, fetuin A, osteoprotegerin, or matrix gla protein were not present in plasma. Thus the control of calcification in bone on the one hand and the preserved solubility of calcium salts in plasma on the other hand are both dependent on the tight control of plasma levels of calcium and phosphate and on the presence/absence of strong inhibitors.
The same reasoning can be applied to urine in which calcium has a concentration of ϳ3 mmol/l and phosphate 10 mmol/l. Inhibitors and promoters of urine crystallization and stone formation have been extensively described (for a review, see Ref. 177) , and calciuria appears to be a major promoter of crystallization and stone formation. Hypercalciuria, as defined either as excretion rate or as concentration, is contributing to Randall's plaque formation and to kidney stone formation (99) . Thus control of calciuria is instrumental in reducing the risk of intrarenal biomineralization and kidney stone formation.
In plasma, only ϳ50% of calcium is freely available, the rest being bound to proteins or forming complexed salts. The concentration of free ionized calcium depends on plasma pH and plasma protein content and constitutes the calcium that is sensed and defended by the organism. It can be measured as ionized calcium.
In the kidney, the only source of calcium reaching the tubules is ultrafiltrated calcium, consisting of ionized calcium and other calcium-containing salts filtered through the glomerulus. It represents ϳ50% of the total plasma calcium, but it is impossible to be precisely measured in a clinical setting. This constitutes a major caveat when it comes to evaluating the fractional excretion of calcium. No secretion or backleak of calcium contributes to the calcium delivered to the tubular system and, consequently, the load of calcium filtered is the unique and major contributor of calcium reaching the proximal tubule (PT). Along the tubular system, complex transepithelial transport mechanisms allow a highly regulated reabsorption of ϳ98% of filtrated calcium (Fig. 1) . In certain circumstances though, the tubular reabsorption system may be overwhelmed by the filtrated load, as seen in primary hyperparathyroidism or in vitamin D intoxication. In these two conditions, the calcium reabsorption machinery of the kidney is maximally stimulated but cannot counterbalance the filtered calcium load, leading to hypercalciuria.
Two main transepithelial calcium transport pathways have been described along the tubules of the kidneys: paracellular and transcellular (Fig. 1) . Paracellular pathways are dependent on transepithelial electrochemical gradients and can be regulated by specialized paracellular proteins, the claudins. The transcellular path implies the presence of a tight epithelium and a three-step transport with apical entry, transcytoplasmic transport, and basolateral extrusion mechanisms. The driving force is mainly provided by basolateral Ca-or Na-K-ATPases.
The following part of this review will address the way calcium is reabsorbed in the different parts of the tubular system.
PT
The PT reabsorbs ϳ60 -70% of the calcium filtered by the glomerulus (Fig. 1) (54) . The majority of the calcium is reabsorbed by passive, hormone-independent, paracellular transport through the remarkably permeable epithelium of the PT (Fig. 2A) . The mechanisms of calcium reabsorption in the PT are complex, due to the heterogenous architecture of the PT, that includes a first cortical convoluted part, displaying a short initial negative luminal transepithelial potential difference (PD), followed by a lumen-positive PD along the other segments of the PT (159) . Calcium permeability in the proximal segment is globally high, but the tubular fluid over plasma filtrate calcium concentration ratio (TF/P) increases slightly in the late PT, maybe due to decrased paracellular transport compared with water in these segments or to formation of luminal calcium complexes. The passive transport is, however, heavily influenced by sodium, chloride, bicarbonate, and potassium availability and by sodium backleak (202, 205) .
Despite the relatively leaky epithelium, several epithelial tight junction proteins called claudins are expressed in the PT Claudins play a key role in the control of paracellular sodium and calcium transport in general and have been comprehensively reviewed (76) . They can be categorized according to anion or cation selectivity, and pore-or barrier-forming capacity. The rather pore-forming claudins 2, 10a, and 17 have been reported in the PT (49, 63, 94, 98; reviewed in Ref. 76 ), while Kirk et al. (93) also detected a proximal tubular expression of claudin-11 by immunohistochemistry on human kidney sections. However, the isoform specificity of some anti-claudin-11 antibodies has been challenged (139) .
In support of the high amount of paracellular calcium reabsorption in the PT, these pore-forming claudins can be expected to contribute to calcium homeostasis: Indeed, mice with deletion of the claudin-2 (CLDN2) gene demonstrated decreased fluid reabsorption in micropunctured tubules (171) . The pores formed by claudin-2 in cultured kidney cell mono- Fig. 1 . Renal calcium reabsorption. About 98% of ultrafiltrated calcium is reabsorbed along the nephron, paracellularly in the proximal tubule and the thick ascending limb (TAL) of the loop of Henle and transcellularly in the distal convoluted and connecting tubules (DCT-CNT). No reabsorption is taking place in the collecting duct, so that this segment is dependent on the load of calcium delivered by the connecting tubule and on its ability to defend against precipitation by diluting and acidifying the final urine. Fig. 2 . Detailed calcium reabsorption per segment. A: proximal tubule. Calcium is mainly reabsorbed paracellularly, partially driven by the activity of the sodium/proton exchanger 3 (NHE3 or SLC9A3), which allows transcellular sodium entry at the apical brush border side of cells, while the Na-K-ATPase pumps sodium out of the cell at the basolateral side. B: thick ascending limb. Calcium is reabsorbed by specialized and controlled paracellular pathways involving claudin 16, 19, and 14. The driving force is provided by sodium reabsorption through the sodium/potassium/chloride cotransporter (NKCC2 or SLC12A1) and the basolateral Na-K-ATPase. Rising interstitial calcium concentrations activate the basolateral calcium-sensing receptor (CaSR), which reduces NKCC2 activity and directly modulates paracellular calcium permeability. C: DCT-CNT. Calcium enters the cell at the apical side through TRPV5 channels, binds intracellular calbindin D-28k, and exits the cell at the basolateral side by 2 pathways: the sodium/calcium exchanger (NCX1 or SLC8A1) and the calcium ATPase PMCA4. Sodium enters the cell via NCC (DCT1) or epithelial sodium channel (ENaC; DCT2 and CNT) and exits through the basolateral Na-K-ATPase. D: collecting duct. No calcium reabsorption is taking place in this segment, which totally depends on the calcium load delivered by the CNT. Apical CaSR-like proteins sense urine calcium concentration. This leads to inhibition of water reabsorption and stimulates urine acidification, decreasing the risk of stone formation. AQP2, aquaporin-2.
layers are cation selective (214) and force sodium and calcium ions to compete to be absorbed (215) . Claudin-2 regulation seems rather complex: A high-sodium diet in rats leads to an upregulation of claudin-2 mRNA levels, but to a downregulation of claudin-2 protein abundance. In addition, these rats displayed increased TRPV5 mRNA and protein in the distal tubule to presumably compensate for the decreased claudin-2 protein expression in the proximal tubule (213) . Interestingly, claudin-2 was also shown to compensate for impaired calcium transport in the duodenum of calbindin 9K (KO) mice, indicating broader regulation of claudin-2 in relation to calcium transport (83) .
Not all calcium transport in the PT is passive and gradient driven. Active calcium transport in the pars recta of the PT has been reported to account for up to 20 -30% of total calcium flux over the PT epithelium in rabbit microperfusion experiments (168) . A precise description of the molecular entities involved in this transport has not been given so far, but transepithelial voltage-dependent L-type calcium channels (216) and the transient receptor potential channel 1 (57) have been observed in the apical membrane of PT cells. However, they rather contribute to calcium-mediated intracellular signaling than to calcium reabsorption (113, 148) .
A crucial function of the PT is the reabsorption of bicarbonate to prevent loss of systemic bases and metabolic acidosis. This process is mediated by transmembrane diffusion of carbon dioxide that is formed by the bicarbonate filtrated in the glomerulus and a proton luminally secreted from proximal tubular epithelial cells. One transporter predominantly responsible for proton secretion in the lumen of the PT is the sodium/proton exchanger 3 (NHE3) (4, 14, 172) . NHE3 highlights the link between sodium and calcium reabsorption yet again, because genetic ablation of NHE3 in mice leads not only to impaired proximal tubular fluid and bicarbonate reabsorption (172) but also to hypercalciuria and osteopenia (147) . NHE3 activity and expression are regulated and inhibited by parathyroid hormone (PTH), supporting a possible role of NHE3, albeit an indirect one, in renal calcium handling (56).
Proximal tubular cells exert further functions only indirectly related to calcium reabsorption but very crucial for proper calcium and phosphate homeostasis: they express the cytoplasmic 1␣-hydroxylase enzyme encoded by the CYP27B1 gene (190) . The role of this enzyme in vitamin D metabolism will be discussed in the section on distal tubular calcium transport.
A cation-sensing G protein-coupled receptor, the calciumsensing receptor (CaSR) (26), has emerged as a key molecule controlling ionized calcium levels through its activity in the parathyroid gland (27) as well as in the kidney (118) . While controversies persist regarding the precise localization and tubular expression pattern, or even isoform, of CaSR in the kidney, some authors have reported an apical expression of CaSR in the epithelium of the PT, which might be regulated by vitamin D and by PTH (25, 29, 51). Activation of the CaSR, in turn, was reported to alter the expression of the vitamin D receptor in proximal tubular kidney cells (123) . Capasso and colleagues (30) looked into whether CaSR might be functionally relevant in the PT. In micropunctured rat and microperfused mouse PT, activation of the CaSR increased fluid reabsorption (30). Furthermore, proximal tubular proton secretion was increased by CaSR activation, confirming the presence and functionality of a calcium-sensing mechanism in this segment, even if immunolabeling of CaSR is disputed (30, 118).
As tubular segments can adapt to events taking place in other tubular segments, Bergsland et al. (11) explored whether proximal tubules might contribute to the increased calcium reabsorption in patients with idiopathic hypercalciuria upon hydrochlorothiazide treatment. It has been suggested that thiazide, a diuretic blocking the Na-Cl cotransporter (NCC) in the distal convoluted tubule (DCT) and having hypocalciuric effects, may exert its effect by stimulating sodium and calcium reabsorption in the PT (142) . Using the fractional excretion (FE) of lithium as a surrogate marker of proximal sodium reabsorption, Bergsland et al. (11) showed in humans that, indeed, sodium is more avidly reabsorbed upon thiazide treatment and this is correlated with increased calcium reabsorption. An earlier study supports these conclusions: Thiazide acutely induced urinary sodium loss and a serum calcium elevation in healthy subjects, but serum calcium elevation was prevented by perfusion of sodium chloride (24). These two studies and others have established the PT as one of the main regulatory segments for calcium reabsorption, intimately linked to sodium and volume reabsorption.
Thick Ascending Limb
After the thin descending and the thin ascending limb of the loop of Henle with very low calcium permeability (167), the thick ascending limb of Henle's loop (TAL) is the next segment of the nephron that significantly reabsorbs calcium. About 25% of the filtered calcium is reabsorbed in a paracellular manner in this segment and is also highly dependent on sodium reabsorption (Fig. 1) . The most studied transport process in the TAL is related to sodium chloride reabsorption by the apical Na-K-Cl cotransporter type 2 (NKCC2) (Fig. 2B) . NKCC2 is present in both the medullary and cortical TAL (85) and is accompanied by an inward-rectifier potassium channel (ROMK) (68) , allowing secretion of potassium back to the tubular lumen, thereby generating a positive transepithelial PD. Due to the lumen-positive PD, calcium transits from the lumen to the interstitium using paracellular pathways (20, 40). The importance of NKCC2 and the positive luminal potential is highlighted by human mutations in the genes coding for NKCC2 (181) and ROMK (182) that lead to Bartter syndrome types 1 and 2, respectively. This syndrome is characterized by salt-wasting, hypokalemic alkalosis, and hypercalciuria. Humans alike, mouse models with disruption of NKCC2 (189) or ROMK (120) exhibit polyuria and hypercalciuria. Taken together, these data strongly support the role of sodium, chloride, and potassium reabsorption in paracellular calcium reabsorption. This further highlights the strong link between sodium and calcium reabsorption in the TAL.
Paracellular transport of calcium. Paracellular calcium transport in the TAL is facilitated by claudins, such as the cation-selective pore-forming claudins 10 and 16, and the anion-blocking claudin-19 (76) . Claudin-16 and claudin-19 are hemichannels that form a paracellular pore permeable to calcium in the TAL. This has been shown in vitro (75, 78) and in vivo (77, 79) .
Claudin-16 was the first claudin to gain clinicians' attention due to its role in calcium homeostasis (Table 1) . Under the name of paracellin-1, mutations in this gene were reported to cause (183) the rare familial hypomagnesemia hypercalciuria syndrome (130) , later named familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), due to intrarenal mineral deposits that progressively lead to renal failure. The patients suffering from mutations in CLDN16 have a selective calcium and magnesium reabsorption deficiency, as illustrated by functional studies performed in these patients. Blocking NKCC2 with furosemide increases urinary sodium, chloride, calcium, and magnesium excretion in healthy subjects, but only sodium and chloride excretion in patients with FHHNC (16). In the same report, Blanchard et al. (16) showed that magnesium and calcium compete for claudin-16-dependent reabsorption. The hypercalciuric response upon magnesium chloride and furosemide cotreatment was blunted in the patients with CLDN16 mutation (16). Over 20 FHHNC disease-causing mutations in CLDN16 have been reported since (57, 136, 137, 180, 204) , which lead to intracellular retention, proteosomal degradation, or impaired paracellular magnesium transport (90) . Interestingly, one specific mutant which is internalized from the plasma membrane too rapidly was stabilized at the cell surface by inhibitors of endocytosis in MadinDarby canine kidney (MDCK) cells, which might be a therapeutic approach for patients carrying the mutation and developing the disease (135) .
In mice with downregulated CLDN16 gene expression by RNA interference, Hou et al. (79) were able to reproduce the urinary calcium-and magnesium-wasting phenotype and nephrocalcinosis seen in human FHHNC patients. Himmerkus et al. (67) used the same mouse model to provide evidence for further involvement of claudin-16 in urinary pH, flow, and bicarbonate excretion. They also observed tubular sodium loss in the TAL of claudin-16 knockdown mice, when the distal tubular sodium absorption was blocked by amiloride treatment. The loss of claudin-16 activity in mice was partially compensated in distal segments by increased urinary acidification (preventing calcium-phosphate precipitation; see hereafter under Collecting Duct) and increased expression of distal calcium and magnesium transporters such as TRPV5, TRPV6, calbindin-D9K, and TRPM6 (208) .
When CLDN16-negative families were screened, a recessive disease locus was mapped and further identified as CLDN19 (97) . CLDN19-mutated patients may have a greater risk for progression to chronic renal disease than CLDN16 (36).
No loss-of-function mutations in humans have been reported for the third member of the claudin family identified in the TAL, CLDN10. A mouse model with TAL-specific inactivation of CLDN10 was established by Breiderhoff et al. (23). Interestingly, the mice displayed higher serum magnesium, while serum calcium was decreased. Accordingly, urinary magnesium excretion was decreased and calcium excretion unchanged, and urine was more acidic and could not be concentrated. Despite a compensatory upregulation of CLDN16 and CLDN19 gene expression, the CLDN10 conditional KO mice had nephrocalcinosis in the outer medulla (23).
Paracellular transport regulation. Several mechanisms have been reported on how claudin-facilitated calcium transport in the TAL is regulated.
First, calcium reabsorption in the TAL is dependent on transepithelial PD (20) and therefore on transcellular sodium reabsorption through NKCC2. Sodium may directly modulate calcium reabsorption, as was reported from MDCK cells expressing CLDN16 (62) . The mirror experiment was performed in dogs infused with calcium chloride, which showed decreased sodium fluxes in TAL (173) . Along the same line, chronic hypercalcemia induced by 1,25(OH) 2 -vitamin D in rats led to the same effect in the TAL (152) .
Second, tubular magnesium competes with calcium reabsorption in claudin-16-deficient patients (16), while in cells it was shown that extracellular magnesium concentration regulates the promoter activity of the CLDN16 gene (47).
Third, the tight junction protein claudin-14 interferes with claudin-16-mediated calcium transport in the TAL. Claudin-14 has an anion barrier function and interacts with claudin-16 (60). The CLDN14 gene was mainly studied for its role in deafness in humans (207) and mice (10) , but a genome-wide association study linked CLDN14 variants to hypercalciuric nephrolithiasis and decreased bone mineral density (191) . Gong et al. (59, 60) showed that dietary calcium affects renal claudin-14 expression by micro-RNA (miRNA)-mediated degradation of the claudin-14 message. Deletion of the CLDN14 gene in mice caused hypocalciuria, hypomagnesiuria, and hypermagnesemia under a high dietary calcium condition (60). See the text for definitions.
Recently, CLDN14 was shown to be highly regulated by epigenetic factors, opening new possibilities of regulation for calcium reabsorption (58) . Finally, CaSR is a crucial regulator of paracellular calcium transport in the TAL. There is a large consensus regarding CaSR expression at the basolateral membrane of the TAL (118, 143, 166) , but its precise role has been only recently elucidated. In a very elegant and complete study, Loupy et al. (118) showed that CaSR mainly regulates the paracellular calciumreabsorbing pathways by a still elusive mechanism and probably less so NKCC2, in contrast to previous beliefs. In vitro studies have suggested that CaSR regulates the claudin-16/19 complex, as well as claudin-14: claudin-16 phosphorylation was decreased and cellular localization altered upon CaSR activation in cells (86)], and CLDN14 transcript levels were increased in mice treated with a CaSR agonist (43). Accordingly, mice with kidney-specific ablation of the CaSR gene displayed downregulated CLDN14 and upregulated CLDN16 expression (193) . Along the same line, it was observed that miRNA regulation of CLDN14 mRNA is controlled by the CaSR (59, 60) . In conclusion, the CaSR in the TAL inhibits passive calcium reabsorption mediated by the paracellular claudin network.
The significance of the CaSR for renal calcium handling in humans has been also supported by several genome-wide association studies for serum calcium that have discovered several common CaSR variants influencing calcium levels (89, 143, 144) . Population-based studies associated the CaSR gene also with urinary calcium (88) and nephrolithiasis (176, 201) .
Mirror monogenic diseases show the importance of CaSR for calcium homeostasis. On one hand, familial hypocalciuric hypercalcemia (FHH) is due to loss-of-function mutation of the CaSR (126) . This disease was first recognized as an autosomaldominant disorder of the parathyroid gland, in which the calcium-sensing process is altered and leads to higher plasma level of calcium and unsuppressed PTH (52). It was named familial benign hypercalcemia. However, some cases of neonatal severe primary hyperparathyroidism (127) have gained distinct attention and were later shown to be the homozygous form of FHH (157) . In 1993, the underlying molecular defect was recognized as a missense mutation in the CaSR (155) . On the other hand, activating missense mutations of the CaSR were identified as the cause of autosomal dominant hypocalcemia with hypercalciuria (82, 149, 156, 158) .
The CaSR is linked to other regulatory pathways of calcium homeostasis, such as 1,25(OH) 2 -vitamin D (1) or PTH (112, 199) . While Toka et al. (193) had already proposed a PTHindependent action of the CaSR in mice with kidney-specific deletion of the CaSR gene that displayed hypocalciuria, further evidence was established by Loupy et al. (118) , who clamped calcium-dependent PTH secretion in rats by performing thyroparathyroidectomy and continuous PTH replacement for their experiments. This approach allowed a precise dissection of the role of renal CaSR independently from systemic influences of PTH. It stressed the importance of renal CaSRdependent calcium reabsorption for the whole calcium homeostasis.
CaSR can be directly modulated by agonists such as cinacalcet (43, 153) or by antagonists and leads to respectively hyper-and hypocalciuria. Of note, calcimimetics have been used to correct the effect of inactivating CaSR mutations (119, 169) .
Calcium transport in the TAL is additionally under the influence of calcitropic hormones. In the cortical portion of the TAL, calcium reabsorption is stimulated by PTH (21, 22), even independently from transepithelial voltage (118) . However, the precise effect of PTH on transepithelial voltage in the TAL remains unclear (209) .
The role of vitamin D on TAL-mediated calcium reabsorption is not well established. In rats treated with 1,25(OH) 2 -vitamin D and rendered hypercalcemic, a decreased expression of NKCC2 and ROMK has been observed, explaining the polyuria associated with hypercalcemia (203) 
Calcium transport is stimulated by calcitonin in the medullary, but not the cortical portion of the TAL (41, 188), where calcitonin receptors are expressed. The physiological relevance of this stimulation is unknown, however.
Besides paracellular calcium transport in the TAL, some studies (21, 22) have reported marginal transcellular calcium transport via proteins yet to be defined, but this is likely of minimal importance.
DCT and Connecting Tubule
Up to 10% of the ultrafiltered calcium reaches the DCT and connecting tubule (DCT-CNT) ( Fig. 1) (37, 196) . No relevant paracellular transport occurs in this segment, where the epithelium is tight and expresses claudins 3, 7, and 8 with no cation pore properties (5, 94, 110; reviewed in Ref. 76) .
Mechanisms of transport. Transcellular calcium reabsorption in the DCT-CNT occurs in three steps (Fig. 2C ): 1) apical calcium entry through transient receptor potential cation channel subfamily V member 5 and/or 6 (TRPV5-6) (70, 72, 150) is followed by 2) intracellular buffering by calbindins (96); 3) at the basolateral side, calcium is exiting the DCT-CNT cell via the calcium-ATPase PMCA4 (122, 185, 200) and the sodiumcalcium exchanger NCX1 (121, 206) .
The transport protein responsible for apical entry of calcium into the tubular cells of the distal nephron had long remained elusive, and the discovery of dihydropyridine (verapamil)-sensitive cardiac L-type calcium channels was once believed to fill the gap (reviewed in Ref. 114 ). However, disruption of one essential component of the channel (CACNB3) in mice induced only a minor phenotype and only after challenges by chlorthiazide treatment (12) .
This changed when a calcium channel was cloned from rabbit kidney and named epithelial calcium channel 1 (ECaC-1) (72) . At the same time, the rat homolog was cloned from kidney and named calcium transporter 2 (CaT-2) (150). The now-called TRPV5 was found strongly expressed in the DCT and the CNT uniquely at the apical side (70) . It was subsequently shown that TRPV5's expression is stimulated by 1,25(OH) 2 vitamin D and PTH and that TRPV5-mediated calcium reabsorption was activated by cellular hyperpolarization and by cytosolic calcium (71, 73) . The function of TRPV5 in vivo was demonstrated in mice deleted for TRPV5: they exhibited renal calcium wasting, increased intestinal calcium absorption, and a decreased bone mass (74, 117) . These mice displayed a sharp downregulation of calbindin binding protein (CaBP)-D28K, by an unknown vitamin D-independent mechanism, and an upregulation of the closely related calcium channel transporter TRPV6 (74) , which forms heterotetramers with TRPV5.
Although this mouse model revealed a dramatic function of TRPV5 in vivo, with loss of function leading to severe hypercalciuria, no TRPV5 variant has been associated with hypercalciuria or kidney stone formation in humans so far (162) .
CaBP-D28K is a cytosolic protein expressed in the DCT-CNT of the kidney (64) able to buffer intracellular calcium (50, 184). Its role in calcium handling is debated, however, as loss-of-function mouse models have only inconsistently shown hypercalciuria (3, 105) . This may be due to an alternative calcium-binding system (calbindin-9, parvalbumin) or regulation, although, when a double CaBP-D28K and CaBP-D9K KO mouse model was studied, disturbed calcium homeostasis with lower bone density was observed under a low-calcium diet (95) .
Parvalbumin is an intracellular calcium-binding protein found in the early DCT (9, 15, 154), after it had long been known to be present in muscle fibers and neurons (32, 146). A direct role for parvalbumin in distal tubular calcium reabsorption remains in question, but it was implicated in NCC regulation, and hypocalciuria was accentuated in parvalbumin KO mice compared with wild-type mice upon hydrochlorothiazide treatment (9) . At the basolateral side of the DCT-CNT cells, two systems are involved in the exit of calcium: the calcium P-ATPases and the calcium/sodium exchanger NCX1. Two main types of calcium ATPases have been identified in the kidney: PMCA1 and PMCA4 (185) . For a while, PMCA1b was considered as quantitatively more important, but recent work has shown that PMCA4 is the main regulated calcium-transporting ATPase. This is based on two lines of evidence: 1) PMCA4 is highly enriched in DCT-CNT tubular cells and 2) PMCA4 is downregulated in TRPV5-KO animals, indicating that interference with calcium transport affects PMCA4 expression (200) .
The sodium-calcium exchanger NCX1 (or SLC8A1) is a key molecule for basolateral calcium export (121, 122, 206) but can also work in the reverse mode, depending on the electrochemical gradients. NCX1 is part of a widely distributed family of electrogenic solute antiporters that exchange sodium for calcium ions with different types of stoichiometry (3Na:1Ca in its main electrogenic mode) (160, 17; reviewed in Ref. 92) . One study showed that other members of the NCX family might be also expressed in the kidney (NCX2) (61), but this was not reported by other studies (107) .
The relative contributions of NCX1 and PMCA pumps for basolateral calcium export are debated, but a mathematical model of calcium reabsorption in the DCT/CNT proposed that NCX1 is the main regulated basolateral exit pathway, while PMCA has housekeeping functions (18). Moreover, NCX1 presents two specificities over PMCA: it is dependent on the transmembrane sodium gradient and on the transepithelial voltage in the DCT. Although calcium reabsorption in the distal nephron is rather sodium independent compared with the PT and TAL, NCX1 activity is an exception. Under normal conditions, NCX1 would increase intracellular sodium levels and depolarize the DCT-CNT cell, if its activity were not counterbalanced by the activity of the sodium/potassium ATPase, which pumps sodium out of the cell. If the sodium gradient is inversed in DCT cells, NCX1 exports sodium and imports calcium in the reverse mode (206) . The link between NCX1 and the sodium/potassium ATPase was further confirmed in the developing heart: when the sodium/potassium ATPase is blocked, intracellular calcium levels rose in the presence of NCX1 but not in its absence (164) .
Basolateral NCX1 activity also depends on sodium entry at the apical side of the distal tubular cell: Sodium is transported through the NCC in the early DCT, while it is reabsorbed through the epithelial sodium channel (ENaC) in the late DCT and CNT. The close connection between NCC and NCX1 activity has been studied by Nijenhuis et al. (140) . Rats treated with hydrochlorothiazides, a blocker of NCC activity, have lower NCX1 mRNA levels compared with untreated rats, situations alike in which the rats were sodium depleted. The lowest NCX1 expression was found when both hydrochlorothiazide treatment and sodium depletion were combined. However, a direct connection between NCC and NCX1 is possible only in a short tubular segment, since colocalization of the two transporters only partially occurs at the end of DCT1 and beginning of DCT2 (116) . The interaction between NCCmediated apical sodium entry and basolateral NCX1 activity is even more complex, as hydrochlorothiazide treatment was affecting not only NCX1 expression levels but also those of TRPV5 and calbindin-D28K (140) . A direct interaction between ENaC and NCX1 or the effect of amiloride, the blocker of ENaC, on NCX1 activity has not been reported so far.
Transport regulation in DCT-CNT. While the paracellular calcium and magnesium reabsorption in the proximal nephron is dependent on salt load, it is less recognized that also transcellular calcium transport in the distal nephron is regulated by the solute load: In two studies with rats, a high-salt diet increased calcium and magnesium excretion but induced a compensatory upregulation of TRPV5, TRPV6, CaBP-D28K, NCX1, and the apical magnesium transporter TRPM6 in the DCT-CNT (106, 214) . Conversely, a low dietary sodium chloride load decreased the expression of these transporters. Possibly, part of this effect may be mediated by the CaSR, which has been reported to be expressed in the DCT-CNT (31, 165). In cells, activation of the CaSR increased TRPV5-mediated calcium transport (194) . A high dietary calcium intake decreased renal TRPV5, CaBP-D28K, and -D9K, but left NCX1 and PMCA1b expression unchanged in mice, albeit biased by nonconstant 1,25(OH) 2 -vitamin D (69) . Interestingly, the same report documented a passive upregulation of TRPV5, CaBP-D28K, NCX1, and PMCA1b upon high dietary calcium, when bypassing 1,25(OH) 2 -vitamin D's effects using 1,25(OH) 2 vitamin D-deficient mice. Others confirmed similar effects in a different 25(OH) 2 -vitamin D-deficient mouse model on a highcalcium diet (111) . Evidently, the DCT-CNT is the renal tubular segment that is most heavily regulated by hormones (reviewed in Ref. 19 ), but the influence of several actors that modulate transcellular calcium reabsorption has been only recently discovered.
For 1,25(OH) 2 -vitamin D (calcitriol), evidence available from dietary, pharmacological, and genetic approaches in rodents, and from nutritive studies and several monogenetic diseases in humans, showed that calcitriol exerts broad regulatory functions on calcium transport in the kidney (103, 161) .
Many of these stem from the transcellular calcium transport in the DCT-CNT. In brief, calcitriol stimulates active calcium reabsorption by upregulation of all involved calcium transport proteins in the DCT-CNT, by acting on the vitamin D receptor (VDR) [129] , which is a nuclear receptor (134) . 25OH vitamin D is hydroxylated in position 1␣ by the renal enzyme encoded by the CYP27B1 gene (190) . This 1␣-hydroxylase enzyme's expression and activity is stimulated by PTH, calcitonin, and low plasma calcium levels and is inhibited by FGF23, klotho, high calcium plasma levels, and by 1,25-(OH) 2 -vitamin D (53,  55, 138, 179) . In humans, insufficient vitamin D intake and monogenetic diseases due to loss-of-function mutations in CYP27B1 or VDR all lead to functional calcitriol deficiency (hypovitaminosis D or pseudo-hypovitaminosis D), and rickets or osteomalacia. A decreased renal function impairs this regulatory network and disturbs calcium homeostasis. These pathologies have all been reviewed elsewhere (46, 124, 132, 192) . 1,25(OH) 2 -vitamin D is inactivated by 24␣-hydroxylation by an enzyme encoded by the CYP24A1 gene (212) . When this gene is disrupted, infantile hypercalcemia results due to vitamin D toxicity (170) .
PTH is secreted from the parathyroid gland upon a decrease in extracellular calcium levels that inactivates the CaSR (26, 125). PTH activates PTH receptor 1 (PTHR1) over several segments along the nephron (108) . In the PT, PTH regulates 1,25(OH) 2 -vitamin D synthesis, which is needed in the distal nephron to sustain TRPV5, CaBP-D28K, and NCX1 expression levels and prevent urinary calcium wasting (199) . Although PTH decreases proximal tubular sodium and calcium reabsorption, the augmented distal calcium reabsorption decreases urinary calcium excretion (2) .
Calcitonin plays a less significant role in distal tubular transcellular calcium reabsorption than calcitriol and PTH. Its function is antagonistic to that of PTH. The calcitonin receptor is present in the DCT (34, 175), but the molecular mechanism of calcitonin-stimulated calcium reabsorption in the distal nephron is not clear. It does not involve altered TRPV5 or CaBP-D28K (80) .
Furthermore, sex hormones specifically regulate calcium reabsorption in the distal nephron: 17␤-estradiol stimulated TRPV5 expression in ovariectomized rats and also independently from calcitriol in mice (198) . It also increased PMCA activity in distal tubular cells (42). Conversely, estrogen deficiency in combination with a low-calcium diet decreased renal TRPV5, CaBP-D28K, and PMCA1b (45). The influence of androgens on calcium transport is less clear. Testosterone has been reported to increase calcium reabsorption in rabbit distal tubule suspensions (38). However, in androgen-deficient mice, TRPV5 and CaBP-D28K were downregulated, and this was reversible by testosterone treatment (81) .
Much attention has been recently drawn on the role of ␣-Klotho on calcium homeostasis. ␣-Klotho is a single-pass transmembrane protein highly expressed in the distal nephron (100) and can be cleaved and secreted. Klotho has antiaging properties (102) and prevents renal injury (186, 187) . Mutations in mice (100) and humans (28, 84) have provided insights into its role in mineral homeostasis. Many effects of Klotho are 1,25(OH) 2 -vitamin D dependent (195) , since genetic (6, 7, 145) or dietary inactivation of the 1,25(OH) 2 -vitamin D pathway (87, 195) rescued Klotho KO mice from most of their phenotypic features. Moreover, ␣-Klotho stabilizes TRPV5 at the apical cell surface possibly through ␤-glucuronidase activity, hydrolysis, and inhibition of lipid raft-mediated internalization (33, 35, 109). Furthermore, Klotho expression has been associated with the activity of the Na-K-ATPase; extracellular calcium increased PTH secretion in a Klotho-and Na-KATPase-dependent manner in mice and drove transepithelial calcium transport (87) .
Klotho is also closely related to FGF receptor signaling, as it serves as a coreceptor in the signaling of FGF receptors (197) . By that, ␣-Klotho is needed to mediate the effects of the phosphaturic hormone FGF-23 (101) . FGF-23 is a hormone that mainly regulates phosphate homeostasis upon secretion from the bone (131), but mice deficient in FGF-23 also display hypercalcemia and increased calcitriol levels (178) . Only one report has so far given molecular evidence for direct involvement of FGF-23 in distal tubular calcium reabsorption (6): FGF-23 increases TRPV5 apical membrane abundance in wild-type mice and also in VDRdeficient mice. Mice deficient for both FGF-23 and VDR displayed a lower TRPV5 abundance than only VDR-deficient or wild-type mice.
Finally, uromodulin (UMOD) has been known as the most abundant human urinary protein and an intraluminal tubular calcification inhibitor that is secreted from the TAL (8, 66, 151) . Human UMOD mutations cause a variety of tubulointerstitial and cystic kidney diseases (39, 210). In mice with deletion of the UMOD gene, however, urinary crystals have been found (13, 91, 133) . Recently, Wolf et al. (211) demonstrated that this is caused by impaired endocytosis of TRPV5, identifying a further regulator of transcellular calcium transport in the distal nephron.
Collecting Duct
The collecting duct (CD) expresses TRPV6 (141) and members of the calbindin family (115) , but the quantitative contribution of the CD to tubular calcium reabsorption is marginal (Fig. 1) . The CD has been found almost impermeable to calcium in all animals studied so far. This makes this segment particularly vulnerable to the amount of calcium delivered by the upstream tubular segments. Indeed, the CD is the concentrating segment in which water is reabsorbed through the concerted action of vasopressin and aquaporins, thus increasing luminal calcium concentration several-fold depending on the conditions. If the PT, TAL, and DCT-CNT are the segments in which calcium excretion rate is determined (the total amount of calcium excreted per 24 h), the CD determines the final concentration of calcium in urine. By virtue of this, the CD is particularly exposed to the risk of calcium salt precipitation.
Two protective mechanisms against calcium salt precipitation have been identified in this segment: acidification and dilution. Indeed, hypercalciuria elicits urine acidification by a still unknown mechanism. It has been suggested that calcium sensing could intervene through calcium-sensing, receptor-like or equivalent proteins and induce both urine acidification and dilution (163) (Fig. 2D) . In humans, however, a mechanism of urinary dilution in hypercalcuric states has not been established.
Conclusion and Perspectives
Much insight has been gained into an understanding of molecular mechanisms involved in renal calcium reabsorption. However, several important questions remain open.
What is the relationship between the NCC and increased renal calcium reabsorption? Observations have shown that every time that the activity of NCC is increased, calcium reabsorption diminishes and hypercalciuria develops. Conversely, when NCC activity is blocked, calcium reabsorption is increased and calciuria decreases. If a significant part of this effect is due to changes in the proximal calcium reabsorption capacity, unknown local factors still need to be unraveled.
It has been postulated that the basolateral sodium-calcium exchanger (NCX1) might be involved in the transcellular calcium reabsorption taking place in the DCT (18). However, this has not been shown in vivo and will need further study.
Cross talk between the different tubular segments of the kidney has been described for sodium transport, with distal segments compensating for proximal segment failure and, conversely, proximal segments compensating for distal inability in reabsorbing sodium. This has not been precisely studied for calcium reabsorption. Evidence in the mouse shows that when furosemide is blocking calcium reabsorption in the TAL, expression of TRPV5 and NCX1 in the DCT is increased (104) , suggesting the presence of analogous TAL-DCT cross talk. Thiazide diuretic treatment is another example of DCTto-PT cross talk that needs to be better characterized (142) .
Hypercalciuria is often associated with urinary acidification and dilution. This observation was proposed to be mediated by the CaSR. However, several lines of evidence argue against this hypothesis. First, the presence of the CaSR in the cortical collecting duct is highly debatable (118) . Second, CaSR has a K i for calcium of ϳ1.24 mM, which is optimal for plasma and interstitial calcium concentration, but which would not accommodate the large range of calcium concentrations measured in the cortical collecting duct lumen. Finally, blocking CaSR with the calcilytic NPS2143 or JTT-305/MK-5442 hardly changed calciuria in mice (44, 65). However, urine pH and urine dilution were not assessed in these studies. In total, the mechanism by which urine is acidified and diluted in the CD upon hypercalciuria is still unknown, and the molecular identity of the CaSR responsible is unknown.
Proximal calcium reabsorption mechanisms still remain largely unknown. How solvent drag is providing the drive for calcium reabsorption and how it is precisely regulated by sodium, volume, or other factors is poorly understood and should be addressed by further study.
Hypercalciuria is intrically linked to kidney stone formation and to nephrocalcinosis, but how and why calcium precipitates in the kidney are still elusive.
Several human monogenic diseases have given insight into renal calcium transport (see Table 1 ). Further progress on the exact role and structure-function relationship of the claudins in calcium homeostasis can be expected over the next several years. Knowledge of regulatory pathways involving the CaSR and similar calcium-sensing systems has only recently started to be reported. Finally, the role of ␣-Klotho and FGF-23 in relation to 1,25(OH) 2 -vitamin D in the kidneys remains to be further elucidated.
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